TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer

2013 ◽  
Vol 30 (8) ◽  
pp. 993-1007 ◽  
Author(s):  
Paula Fernanda Vázquez ◽  
María José Carlini ◽  
María Cecilia Daroqui ◽  
Lucas Colombo ◽  
Mercedes Liliana Dalurzo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Tgf Beta ◽  
Small Cell Lung ◽  
Murine Lung

Pemetrexed-induced severe rhabdomyolysis in lung cancer: A case report

2018 ◽  
Vol 25 (8) ◽  
pp. 2007-2009 ◽  
Author(s):  
Kevin Sullivan ◽  
Chung-Shien Lee
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

Pemetrexed is an antifolate metabolite used to treat non-small cell lung cancer in the adjuvant and advanced setting. It is commonly known to cause rash, diarrhea, fatigue, mucositis, and myelosuppression. We report a case of a patient receiving adjuvant cisplatin and pemetrexed for non-small cell lung adenocarcinoma and experienced severe rhabdomyolysis.

Synchronous Bilateral Retinal Metastases from Lung Adenocarcinoma

2005 ◽  
Vol 91 (3) ◽  
pp. 287-289 ◽  
Author(s):  
Antonio Rossi ◽  
Andrea Manto ◽  
Paolo Maione ◽  
Cesare Gridelli
Keyword(s):  
Lung Cancer ◽  
Central Nervous System ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Adrenal Glands ◽  
Palliative Radiotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Heavily Pretreated

Hematogenous retinal metastases from non-small cell lung cancer are rare, and are even more uncommonly observed bilaterally. Non-small cell lung cancer usually metastasizes to the liver, adrenal glands, lung, bone, central nervous system, and kidney. We report the case of a 41-year-old male patient with advanced lung adenocarcinoma heavily pretreated with polychemotherapy and palliative radiotherapy up to June 2003, when synchronous bilateral retinal metastases were diagnosed. The patient's prognosis was worsened by the onset of the retinal metastases and he died three months later.

scholarly journals The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types

2021 ◽  
Vol 11 ◽  
Author(s):  
Haiqing Chen ◽  
Fangqiu Fu ◽  
Yue Zhao ◽  
Haoxuan Wu ◽  
Hong Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Tumor Markers ◽  
Cell Lung Cancer ◽  
Carbohydrate Antigen ◽  
Small Cell ◽  
Small Cell Lung ◽  
Serum Tumor Markers ◽  
Preoperative Serum

ObjectivesTo assess the association between common-used serum tumor markers and recurrence of lung adenocarcinoma and squamous cell carcinoma separately and determine the prognostic value of serum tumor markers in lung adenocarcinoma featured as ground glass opacities.MethodsA total of 2,654 non-small cell lung cancer patients undergoing surgical resection between January 2008 and September 2014 were analyzed. The serum levels of carcinoma embryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153) and carbohydrate antigen 199 (CA199) were tested preoperatively. Survival analyses were performed with COX proportional hazard regression.ResultsAmong patients with lung adenocarcinoma, elevated preoperative serum CEA(HR=1.246, 95%CI:1.043-1.488, P=0.015), CYFRA21-1(HR=1.209, 95%CI:1.015-1.441, P=0.034) and CA125(HR=1.361, 95%CI:1.053-1.757, P=0.018) were significantly associated with poorer recurrence free survival (RFS). Elevated preoperative serum CA199 predicted worse RFS in patients diagnosed with lung squamous cell carcinoma (HR=1.833, 95%CI: 1.216-2.762, P=0.004). Preoperative serum CYFRA21-1(HR=1.256, 95%CI:1.044-1.512, P=0.016) and CA125(HR=1.373, 95%CI: 1.050-1.795, P=0.020) were independent prognostic factors for patients with adenocarcinoma presenting as solid nodules while serum CEA (HR=2.160,95%CI:1.311-3.558, P=0.003) and CA125(HR=2.475,95%CI:1.163-5.266, P=0.019) were independent prognostic factors for patients with adenocarcinoma featured as ground glass opacities.ConclusionsThe prognostic significances of preoperative serum tumor markers in non-small cell lung cancer were associated with radiological features and histological types.

scholarly journals Association of PD-1 polymorphisms with the risk and prognosis of lung adenocarcinoma in the northeastern Chinese Han population

2019 ◽  
Author(s):  
Kun huang ◽  
Erqiang Hu ◽  
Wan Li ◽  
Junjie Lv ◽  
Yuehan He ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Information ◽  
Small Cell ◽  
Small Cell Lung ◽  
Chinese Han ◽  
Chi Square ◽  
Han Population

Abstract Introduction Lung cancer is a leading cause of death from cancer worldwide, especially non-small cell lung cancer (NSCLC). The marker of progression in lung adenocarcinoma has been rarely studied. PD-1 is an effective drug target for the treatment of non-small cell lung cancer. The study of the effect of polymorphism on the progression of lung adenocarcinoma in the Han population of Northeast China may provide a valuable reference for the research and application of these drugs. Methods Chi-square test, Wilcoxon rank sum test, and classification efficacy assessment were used to teste SNPs of PD-1 in 287 patients and combined with clinical information. Results We successfully identified biomarkers (rs2227981, rs2227982, and rs3608432) that could distinguish the early stages and late stages of lung adenocarcinoma. Multiple clinical indicators showed significant differences among different SNP typing and cancer stages. Furthermore, this gene was confirmed to effectively distinguish the staging of lung adenocarcinoma with RNA-seq data in TCGA. Conclusions This indicated that the PD-1 gene and the SNPs on it could be used as markers for distinguishing lung adenocarcinoma staging in the Northeast Han population.

scholarly journals Transformation to Small-Cell Lung Cancer Following Treatment with Vandetanib in a Patient with Lung Adenocarcinoma

2014 ◽  
Vol 25 ◽  
pp. v89
Author(s):  
Naoyuki Nogami ◽  
Toshiyuki Kozuki ◽  
Hiromoto Kitajima ◽  
Daijiro Harada ◽  
Shoichiro Yamamoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. TPS2678-TPS2678
Author(s):  
Takefumi Komiya ◽  
Jun Zhang ◽  
Prakash C. Neupane ◽  
Kathan Mehta ◽  
Chao Hui Huang
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Tgf Beta ◽  
Small Cell Lung

TPS2678 Background: Checkpoint inhibitors (CPI) targeting the PD1/PD-L1 axis significantly improved patient outcomes in stage IV non-small cell lung cancer (NSCLC). However, these patients will eventually develop resistance and progression. There is a need to identify novel treatment options. Poor response to PD-L1 antibody was correlated with increase in cancer-associated fibroblasts (CAF), which is known to interact with cytotoxic T cells (CTLs) by suppressing their function in a manner similar to regulatory T cells (Tregs). Production of cytokines by CAFs leads to impaired antitumor immunity by impairing CTL function (TGF beta) and prevent recruitment/mobilization of CTLs into tumors. These effects suggesting that CAF can be a therapeutic target in lung cancer resistant to checkpoint inhibitors. Pirfenidone (P) is approved to treat pulmonary fibrosis with anti-fibrotic effect by blocking the differentiation of fibroblasts into CAFs and suppress the production of TGF beta and TGF beta-induced signaling pathways/collagens. Atezolizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody that targets PD-L1 and inhibits the interaction between PD-L1 and its receptors, PD-1 and B7-1 (CD80), both of which function as inhibitory receptors expressed on T cells. We proposed a phase I/II trial to test the combination of atezolizumab (A) with P in patients with recurrent non-small cell lung cancer (NSCLC) after progression with CPI. The primary objective of phase I is to determine the maximum tolerated (MTD) dose of P in combination with A and assess the safety and tolerability of this combination. The secondary objective is to determine the efficacy of AP in all NSCLC participants treated in this study. Exploratory objectives include the measurement of circulating levels of TGF beta and research in expression of CAF related proteins. Methods: The initial phase I will enroll 3 patients using P at 801 mg po TID. A will be at 1200mg iv every 3 weeks. If there is ≤ 1 DLT, the study will proceed to phase II If there are 2- 3 DLT, P will be reduced to 534 mg TID. If there is ≤ 1 DLT, then this dose will proceed to phase II. If there is 2-3 DLT, then the study will be terminated. The phase II will enroll 16 patients to assess efficacy. Main inclusion criteria are patients with recurrent NSCLC after progression with first-line therapy CPI with or without chemotherapy, measurable disease, ECOG 0-2, and adequate organ function. Clinical trial information: NCT04467723.

scholarly journals An aggressive non-small cell lung cancer in nonsmokers: A case report of an unusual presentation of micropapillary lung adenocarcinoma

2017 ◽  
Vol 20 ◽  
pp. 125-128
Author(s):  
Aixa Dones Rodríguez ◽  
Kelvin Rivera Manzano ◽  
Ricardo Fernández González ◽  
José R. Adorno Fontánez ◽  
Ricardo A. Hernández ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Unusual Presentation ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document